Characterization and deposition of respirable large- and small-particle bioaerosols.
The deposition patterns of large-particle microbiological aerosols within the respiratory tract are not well characterized. A novel system (the flow-focusing aerosol generator [FFAG]) which enables the generation of large (>10-microm) aerosol particles containing microorganisms under laboratory conditions was characterized to permit determination of deposition profiles within the murine respiratory tract. Unlike other systems for generating large aerosol particles, the FFAG is compatible with microbiological containment and the inhalational challenge of animals. By use of entrapped Escherichia coli cells, Bacillus atrophaeus spores, or FluoSphere beads, the properties of aerosols generated by the FFAG were compared with the properties of aerosols generated using the commonly available Collison nebulizer, which preferentially generates small (1- to 3-microm) aerosol particles. More entrapped particulates (15.9- to 19.2-fold) were incorporated into 9- to 17-microm particles generated by the FFAG than by the Collison nebulizer. The 1- to 3-microm particles generated by the Collison nebulizer were more likely to contain a particulate than those generated by the FFAG. E. coli cells aerosolized using the FFAG survived better than those aerosolized using the Collison nebulizer. Aerosols generated by the Collison nebulizer and the FFAG preferentially deposited in the lungs and nasal passages of the murine respiratory tract, respectively. However, significant deposition of material also occurred in the gastrointestinal tract after inhalation of both the small (89.7%)- and large (61.5%)-particle aerosols. The aerosols generated by the Collison nebulizer and the FFAG differ with respect to mass distribution, distribution of the entrapped particulates, bacterial survival, and deposition within the murine respiratory tract.
Thomas
Richard J
RJ
Defence Science and Technology Laboratory, Salisbury, Wiltshire, United Kingdom. rjthomas@dstl.gov.uk
Webber
Daniel
D
Sellors
William
W
Collinge
Aaron
A
Frost
Andrew
A
Stagg
Anthony J
AJ
Bailey
Stephen C
SC
Jayasekera
Pramukh N
PN
Taylor
Rosa R
RR
Eley
Steve
S
Titball
Richard W
RW
D000336:Aerosols / Q000493:pharmacokinetics*; D000818:Animals; D001407:Bacillus / Q000302:isolation & purification; D015169:Colony Count, Microbial; D004926:Escherichia coli / Q000302:isolation & purification; D005260:Female; D041981:Gastrointestinal Tract / Q000382:microbiology; D019570:Inhalation Exposure; D008168:Lung / Q000382:microbiology; D051379:Mice; D008807:Mice, Inbred BALB C; D050296:Microbial Viability; D009296:Nasal Cavity / Q000382:microbiology; D009330:Nebulizers and Vaporizers; D012137:Respiratory System / Q000382:microbiology*
D000336:Aerosols